KOL WEBINAR WITH DR. FRANK GIORDANO
GLORIA Top-Line Results of
NOX-A12 & Radiotherapy Combination
in First-Line Glioblastoma
Presented at ASCO 2022
June 10, 2022| 8:00 AM EDT / 2:00 PM CEST
© NOXXON Pharma
WEBINAR PRESENTERS
MODERATOR
Guillaume van
Renterghem
Managing Director
LifeSci Advisors
PRESENTERS
Dr. Frank Giordano | Aram Mangasarian |
Chair & Director | CEO |
Radiation Oncology Dept. | NOXXON Pharma |
University Hospital Bonn | |
Lead Investigator of NOX-A12 | |
GLORIA Phase 1/2 Study |
2
Glioblastoma is a Devastating Orphan Brain Cancer where the TME Plays a Significant Role
LACK OF EFFECTIVE THERAPIES & LOW OVERALL
SURVIVAL
5Y
Orphan
Status
4% | ||||||||||
29,000 | mOS | ~ 160 active | ||||||||
New Cases | 12-15 months | clinical trials | ||||||||
per year1 |
Glioblastoma Long-Term Survival Rates
100%
100% | ||||
80% | ||||
60% | ||||
40% | ||||
18% | 11% | |||
20% | ||||
4% | ||||
0% | ||||
Diagnosis/ Trial | 2-year | 3-year | 5-year | |
Entry |
HIGH UNMET NEED PATIENT SEGMENTS
- MGMT unmethylated promoter - chemotherapy ineffective
- NOX-A12to focus on MGMT unmethylated patients
- Incomplete resection - poor prognosis & therapeutic responses
1. In the US, UK, FR, ES, DE & IT, Global Data April 2022 | |
3 | Sources: Poon MTC, et al., Scientific Reports 2020 Vol. 10 Issue 1; Hegi ME et al. N Engl J Med 2005;352:997-1003; Global Data, ClinicalTrials.gov & NOXXON Pharma analysis, April 2022 |
Frank A. Giordano, MD
Professor of Radiation Oncology
Director and Chair, Department of Radiation Oncology
University Hospital Bonn
Lead Investigator of NOX-A12 GLORIA Phase 1/2 Study
Study Arms
Dose
Escalation
Cohorts
Recruitment
Completed
OLA-BEV
Cohort
Recruiting
OLA-PEM
Cohort
Recruiting
Key inclusion criteria:
- Newly-diagnosedsupratentorial glioblastoma WHO IV
- MGMT promoter unmethylated
- Incomplete resection/biopsy only
- ECOG ≤ 2
allowing completely
resected GBM with v7.0
allowing completely
resected GBM with v7.0
RT
60 Gy (2 Gy x 30)
40.05 Gy (2.67 Gy
x 15)
OLA | FU |
continuous i.v. infusion at three doses (200, 400, 600 mg/week) | |
16
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Noxxon Pharma NV published this content on 10 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2022 07:32:10 UTC.